AAX Biotech AB
@aaxbiotech.com
AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs in antibody-based medicine development. We aim to be a leading partner for the global biopharmaceutical industry focusing on a broad range of diseases including cancer, autoimmune disorders, and neurological conditions. We are committed to providing unparalleled expertise and innovative technologies that contribute to the advancement of novel antibody therapeutics. Technologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.
AAX Biotech AB's Company Logos
AAX Biotech AB's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#4A5464
River Bed
74, 84, 100
217, 15, 34
26, 16, 0, 61
#9BEFA1
Madang
155, 239, 161
124, 72, 77
35, 0, 33, 6
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
About AAX Biotech AB
AAX Biotech AB is a research-driven biotech company specializing in next-generation antibody therapeutics. Our proprietary Seqitope™ and Opti-mAb™ technologies address crucial issues in drug development, offering solutions that enhance antibody performance and stability. The Seqitope™ technology enables detailed epitope-binding analysis early in drug development, accelerating the process. Opti-mAb™ provides a molecular stabilization strategy for scFv antibodies, improving stability and reducing costs.
Founded by experts Mats Persson and Daniel Johansson from Karolinska Institutet, AAX Biotech is committed to advancing therapies for various diseases, including cancer, autoimmune, and neurological conditions. Our mission is to utilize innovation to meet the unmet needs in therapeutic development, ultimately benefiting patients worldwide. With a team of experienced professionals and a vision to be a top player in the antibody field, AAX Biotech aims to revolutionize antibody-based medicines and lead the way in biopharmaceutical partnerships.
